Stay updated on ALPN-303 Safety and Tolerability Clinical Trial
Sign up to get notified when there's something new on the ALPN-303 Safety and Tolerability Clinical Trial page.

Latest updates to the ALPN-303 Safety and Tolerability Clinical Trial page
- Check6 days agoChange DetectedAdded a Locations section with Queensland and Victoria (Australia) sites; revision updated to v3.3.3.SummaryDifference0.4%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedRevision update: v3.3.2 was added and v3.2.0 was removed.SummaryDifference0.1%

- Check42 days agoChange DetectedRemoved the notice about a lapse in government funding and potential delays in processing, which previously appeared on the page. This is a minor operational banner change that does not affect the study details, eligibility criteria, or data presented on the ClinicalTrials.gov record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check56 days agoChange DetectedScreenshots show only layout and visual adjustments; core study content (intervention, outcomes, eligibility criteria, enrollment, and locations) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check85 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference5%

- Check92 days agoChange Detected- Added revision: v3.1.0. - Removed topics: MedlinePlus drug safety topics and related MeSH terms (Substandard Drugs, Pharmaceutical Preparations, Counterfeit Drugs) and revision reference v3.0.2. Overall, the page now announces a newer version while narrowing the topic scope slightly.SummaryDifference1%

Stay in the know with updates to ALPN-303 Safety and Tolerability Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALPN-303 Safety and Tolerability Clinical Trial page.